Skip Navigation LinksHome > March 2013 - Volume 28 - Issue 2 > In a randomized placebo-controlled add-on study orlistat sig...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e32835b08d2
Original Articles

In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation

Chukhin, Evgenya; Takala, Pirjob; Hakko, Helinäc; Raidma, Mirjamd; Putkonen, Hannab,e; Räsänen, Pirkkof; Terevnikov, Viacheslavd; Stenberg, Jan-Henrya; Eronen, Markkub; Joffe, Grigoria

Collapse Box

Abstract

Constipation is a common and potentially fatal side effect of clozapine treatment. Another important side effect of clozapine may also be significant weight gain. Orlistat is a weight-control medication that is known to induce loose stools as a common side effect. This study aimed to explore whether orlistat used to control clozapine-induced weight gain can simultaneously tackle clozapine-related constipation. In this 16-week randomized-controlled study, clozapine-treated patients received add-on orlistat (n=30) or add-on placebo (n=24). Colonic function was measured using the Bristol Stool Form Scale. There was a significant (P=0.039) difference in the prevalence of constipation in favor of orlistat over placebo in completers (n=40) at the endpoint. A decrease in the prevalence of constipation within the orlistat group (P=0.035) was observed (vs. no statistically significant changes in the placebo group). In clozapine-treated patients, orlistat may be beneficial not only for weight control but also as a laxative. As no established treatments for clozapine-induced constipation exist, orlistat can be considered for this population, although more studies are required.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.